The estimated Net Worth of Amit Rakhit is at least $2.44 Миллион dollars as of 14 July 2021. Amit Rakhit owns over 34,017 units of Ovid Therapeutics Inc stock worth over $852,141 and over the last 7 years he sold OVID stock worth over $0. In addition, he makes $1,590,940 as President и Chief Medical Officer at Ovid Therapeutics Inc.
Amit has made over 1 trades of the Ovid Therapeutics Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 34,017 units of OVID stock worth $64,292 on 14 July 2021.
The largest trade he's ever made was exercising 34,017 units of Ovid Therapeutics Inc stock on 14 July 2021 worth over $64,292. On average, Amit trades about 4,252 units every 0 days since 2018. As of 14 July 2021 he still owns at least 760,840 units of Ovid Therapeutics Inc stock.
You can see the complete history of Amit Rakhit stock trades at the bottom of the page.
Dr. Amit Rakhit M.D. serves as President, Chief Medical Officer of the Company. Dr. Rakhit served as Senior Vice President, Worldwide Medical at Biogen Inc., a publicly held biotechnology company, from March 2014 to March 2016 and as Vice President, Program Leadership & Management from June 2011 to February 2014. Prior to that, he worked at Bristol-Myers Squibb Company from August 2001 to June 2011, where he most recently served as Vice President, Intercontinental Medical. Dr. Rakhit earned his BA in Molecular Biology from the University of California, Berkeley, his MD from Tufts University School of Medicine, his M.S. from Vanderbilt University School of Medicine and dual MBAs from the London Business School and Columbia University. Dr. Rakhit completed his fellowship in pediatric cardiology at Harvard Medical School.
As the President и Chief Medical Officer of Ovid Therapeutics Inc, the total compensation of Amit Rakhit at Ovid Therapeutics Inc is $1,590,940. There are 1 executives at Ovid Therapeutics Inc getting paid more, with Jeremy Levin having the highest compensation of $3,008,980.
Amit Rakhit is 50, he's been the President и Chief Medical Officer of Ovid Therapeutics Inc since 2019. There are 13 older and 3 younger executives at Ovid Therapeutics Inc. The oldest executive at Ovid Therapeutics Inc is Bart Friedman, 75, who is the Lead Independent Director.
Amit's mailing address filed with the SEC is C/O OVID THERAPEUTICS INC., 1460 BROADWAY, SUITE 15044, NEW YORK, NY, 10036.
Over the last 8 years, insiders at Ovid Therapeutics Inc have traded over $37,290 worth of Ovid Therapeutics Inc stock and bought 2,202,070 units worth $5,624,523 . The most active insiders traders include Pharmaceutical Co Ltdmillen..., Barbara Gayle Duncan и Jeremy M Levin. On average, Ovid Therapeutics Inc executives and independent directors trade stock every 218 days with the average trade being worth of $229,440. The most recent stock trade was executed by Jeremy M Levin on 18 March 2024, trading 18,248 units of OVID stock currently worth $50,364.
ovid therapeutics is a biopharmaceutical company focused exclusively on developing impactful medicines for patients and families living with rare neurological disorders. ovid’s drug candidate, ov101, is currently in development for the treatment of symptoms of angelman syndrome and fragile x syndrome. ovid is also developing ov935 in collaboration with takeda pharmaceutical company limited for the treatment of rare epileptic encephalopathies. ovid has initiated the phase 2 stars trial of ov101 in adults with angelman syndrome and a phase 1 trial in adolescents with angelman and fragile x syndrome to identify doses suitable for younger patients. review our community guidelines: http://www.ovidrx.com/community-guidelines/
Ovid Therapeutics Inc executives and other stock owners filed with the SEC include: